SILAC


Also found in: Wikipedia.
AcronymDefinition
SILACStable Isotopes Labeling by Amino Acids in Cell Culture
References in periodicals archive ?
High throughput proteomics (ICPL, SILAC and label-free analysis) will be used to identify new biomarkers of radiation-induced cardiovascular disease for future molecular epidemiological studies.
0 ensures confident information from quantitative studies using either label-free or ICPL[TM]-4plex, SILAC, iTRAQ[TM]-8plex or user-defined label technologies, integrates multiple datasets across large proteomic studies and generates reports in accordance to standard publication guidelines.
In concert, the company announced a co-marketing agreement with Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, to facilitate the introduction of the SILAC technology.
Applied Biosystems will also provide software support for SILAC on its TOF/TOF(TM) family of products, including the newly launched 4800 MALDI TOF/TOF(TM) Analyzer, and plans to extend software support for the SILAC labeling technology to other Applied Biosystems/MDS SCIEX protein mass spectrometry systems.
SILAC protein identification and quantification labeling technology is designed to allow life science researchers, from molecular biologists to biochemists, to take advantage of proteomics applications utilizing mass spectrometry, which may significantly enhance the efficiency and accuracy of drug discovery research.
SILAC technology and ICAT reagents are both protein labeling strategies compatible with 1D gel separation, which is the primary workflow for biologists.
Forward-looking statements include, but are not limited to: 1) Invitrogen's product lines and Applied Biosystems' expertise in mass spectrometry will facilitate the ability to introduce the technology to a broader market; 2) Invitrogen and Applied Biosystems will re-sell a suite of their combined technologies that will include SILAC technology Potential risks and uncertainties include, but are not limited to, the risks: a) The alliance may not drive wider adoption of mass spectrometry applications; and b) Specific technologies in the co-marketing agreement may vary, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.